Expert Analysis

Addressing Side Effects and Coinfections

Source: CCO Independent Conference Coverage of the 2005 Annual Meeting of the American Association for the Study of Liver Diseases*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Addressing Side Effects and Coinfections

Faculty:

Nezam H. Afdhal, MD, FRCPI
Raymond T. Chung, MD
Mark S. Sulkowski, MD

CREDIT INFORMATION

Release Date: January 27, 2006

Expiration Date: January 26, 2007

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.8 Nursing contact hours

Status: The activity is not currently available for credit.

Learning Objectives

Upon completion of this activity, participants should be able to:

Review recent studies of approaches to reduce or avoid common side effects of hepatitis treatment
Discuss groups at higher risk for the development of side effects from treatment
Evaluate recent clinical trials of peginterferon and ribavirin for the treatment of hepatitis C virus infection in HIV-infected patients

Topics covered include:

Epoetin and HCV Therapy: SVR, Anemia, and Quality of Life
Cost-Effectiveness of Treating Chronic Hepatitis C in HIV-Coinfected Patients
Sexual Dysfunction Is Highly Prevalent in Men With Chronic Hepatitis C
Fatigue and Virologic Response During Chronic Hepatitis C Treatment
HIV Testing in Patients With Chronic Hepatitis C and a Plea for Vaccination
Does Type and Duration of Antiretroviral Therapy Attenuate Liver Fibrosis in HIV/HCV-Coinfected Patients?
Managing HBV in HIV-Coinfected Patients
Association Between SVR and ALT in APRICOT
Impact of HCV Therapy on Fibrosis Progression in HIV Coinfection
24 Weeks of Peginterferon/Ribavirin for Acute HCV Infection in HIV-Positive Patients

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.